The Leukemia & Lymphoma Society (LLS)
This organization has already been registered
Someone in your organization has already registered and setup an account. would you like to join their team?Profile owner : m***********s@l*s.o*g
Mission Statement
Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.
About This Cause
NOTE: If you would like to direct your donation to a specific region of The Leukemia & Lymphoma Society (LLS), please use the "comments" section in your donation form to address where you would like your donation designated. LLS Mission The mission of LLS is to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving cancer research around the world and provides free information and support services to blood cancer patients and their families. Organization Description The Leukemia & Lymphoma Society (LLS) was born out of a family's grief following the death of their son, who was 16 when he succumbed to leukemia in 1944. Frustrated by the lack of effective treatments for what was then a hopeless disease, parents Rudolph and Antoinette de Villiers started a fundraising and education organization. Driven by the de Villiers's nearly boundless belief that leukemia was indeed curable, the foundation grew steadily, opening its first offices in the New York City area. Today, LLS, a 501(c)(3) organization, is the largest not-for-profit health agency dedicated to finding cures and better treatments for people with blood cancer, funding cutting-edge research worldwide to advance breakthrough therapies and bring them to more patients faster. With the size and scope to fund research on a scale that makes progress happen, LLS funds more blood cancer research than any other organization. Advised by leading biomedical research and clinical experts, LLS identifies and funds the most promising blood cancer research found anywhere and has invested more than $1.3 billion in research to advance therapies and save lives. Unlike corporations that invest in drugs offering the best profit potential, LLS funds research based on unmet medical needs of blood cancer patients, without restriction by commercial return, market size or geography. LLS recognizes that finding cures is not enough; we must ensure that patients have access to the treatments they need. Through diverse and extensive outreach initiatives, we advocate, educate, assist and support patients and fight for them at the national and state levels. With the help of trained volunteers, our policy team influences crucial legislation to accelerate research and break down barriers to treatment. Each year, our Information Specialists, all master’s-level health care professionals, respond to nearly 20,000 inquiries, and that number continues to grow. Annually, LLS distributes 600,000 educational booklets and fact sheets about specific diseases to patients and families around the country. And in 2019, more than 600 patients received in-depth clinical trial support from our industry-leading Clinical Trial Support Center. A support to patients when they need it most, LLS distributed nearly $5 million in relief funds to more than 19,000 patients during the global pandemic. History LLS was born out of a family's grief following the death of their son, who was 16 years old when he succumbed to leukemia in 1944. Five years later, frustrated by the lack of effective treatments for what was then considered a hopeless disease, parents Rudolph and Antoinette de Villiers started a fundraising and education organization in their son's name. The task was daunting. Most leukemia patients, especially children, died within three months. Driven by the de Villiers' belief that leukemia was indeed curable, the foundation grew steadily, opening its first offices in the New York City area. Today, LLS is the largest voluntary health agency dedicated to funding research, finding cures and ensuring access to treatments for patients. A philanthropic, service-driven organization, our reach and impact are profound. With 27 regional teams working in 70 offices to support communities across the United States, LLS’s vision is to support all patients and families coping with a blood cancer diagnosis. With both a fundraising and patient support agenda, each regional team is a resource for patients, families and healthcare professionals, raising awareness and providing services in communities across the country. Critical fundraising efforts provide resources to fuel the three distinct and interrelated pillars of the LLS mission: research, patient access, and advocacy. Research-focused Our donor partnerships have made possible an investment of more than $1.3 billion in research since our founding 70 years ago, and together we have contributed to virtually every major development in the treatment of blood cancers. Since inception, LLS has established a track record of involvement in groundbreaking advancements. In 1951, the research of LLS advisers George H. Hitchings, PhD, and Gertrude B. Elion, DSc, led to the most widely used antileukemia drugs, earning Hitchings and Elion them the 1988 Nobel Prize in Physiology or Medicine. LLS adviser J. Michael Bishop, MD, also a Nobel Prize winner, established an early understanding of the genetics of cancer with the discovery of oncogenes in the 1970s. One of our first grant recipients, James Holland, MD, pioneered combination therapy for blood cancer. More recently, LLS support helped Brian Druker, MD, develop the breakthrough drug Gleevec, and we partnered with Carl June, MD, in realizing CAR (chimeric antigen receptor) T-cell immunotherapy. The cumulative impact of seven decades of investment in better treatments is profound and has led to significant increases in survival rates: blood cancer mortality has seen an average decline of 32 percent over the past three decades and continues to drop. Problem/Need Progress is critical for the nearly 1.4 million people in the United States who are living with or in remission from blood cancer. This year alone, leukemia, lymphoma or myeloma will be diagnosed in 176,200 people. That amounts to one person receiving a blood cancer diagnosis every three minutes. Of those people, more than one-third will not survive five years after their diagnosis. One life is lost to blood cancer every nine minutes in the United States. Cures are meaningful only when they are available to the patients who need them. LLS’s mission focuses on equally supporting patients, families and health care professionals with information, education and access to the very best care possible. Representing the interests of patients and families, we fight for public policy at the state and federal levels to ensure that patients receive quality, affordable, coordinated care. CAMPAIGN DESCRIPTIONS: LIGHT THE NIGHT: A community event where patients, caregivers and supporters walk to celebrate, honor and remember those touched by cancer. Together we bright light to the darkness of cancer. https://www.lightthenight.org/ BIG CLIMB: Step up to take down cancer by climbing to the top of iconic skyscrapers across the country. Supporting patients and raising funds as we Climb. Conquer. Cure. https://www.lls.org/big-climb MAN & WOMAN OF THE YEAR: A philanthropic competition to support blood cancer research among a group of motivated and dedicated individuals in communities across the United States. https://www.mwoy.org/ STUDENTS OF THE YEAR: A philanthropic leadership development program for exemplary high school students. Participants foster professional skills such as entrepreneurship, marketing, and project management all while raising money to help cure cancer. https://studentsoftheyear.org/